| Literature DB >> 30523111 |
Sandra Ackermann1,2, Maria Cartolano2,3, Barbara Hero4, Anne Welte1,2, Yvonne Kahlert1,2, Andrea Roderwieser1,2, Christoph Bartenhagen1,2, Esther Walter1,2, Judith Gecht4, Laura Kerschke5, Ruth Volland4, Roopika Menon6, Johannes M Heuckmann6, Moritz Gartlgruber7, Sabine Hartlieb7, Kai-Oliver Henrich7, Konstantin Okonechnikov8, Janine Altmüller2,9, Peter Nürnberg2,9,10, Steve Lefever11, Bram de Wilde11, Frederik Sand1,2, Fakhera Ikram1,2,12, Carolina Rosswog1,2, Janina Fischer1,2, Jessica Theissen1,4, Falk Hertwig1,2,13,14,15, Aatur D Singhi16, Thorsten Simon4, Wenzel Vogel17,18, Sven Perner17,18, Barbara Krug19, Matthias Schmidt20, Sven Rahmann21,22, Viktor Achter23, Ulrich Lang23,24, Christian Vokuhl25, Monika Ortmann26, Reinhard Büttner26, Angelika Eggert13,14,15, Frank Speleman11, Roderick J O'Sullivan27, Roman K Thomas3,14,26,28, Frank Berthold4, Jo Vandesompele11, Alexander Schramm29, Frank Westermann7, Johannes H Schulte13,14,15,28, Martin Peifer2,3, Matthias Fischer30,2.
Abstract
Neuroblastoma is a pediatric tumor of the sympathetic nervous system. Its clinical course ranges from spontaneous tumor regression to fatal progression. To investigate the molecular features of the divergent tumor subtypes, we performed genome sequencing on 416 pretreatment neuroblastomas and assessed telomere maintenance mechanisms in 208 of these tumors. We found that patients whose tumors lacked telomere maintenance mechanisms had an excellent prognosis, whereas the prognosis of patients whose tumors harbored telomere maintenance mechanisms was substantially worse. Survival rates were lowest for neuroblastoma patients whose tumors harbored telomere maintenance mechanisms in combination with RAS and/or p53 pathway mutations. Spontaneous tumor regression occurred both in the presence and absence of these mutations in patients with telomere maintenance-negative tumors. On the basis of these data, we propose a mechanistic classification of neuroblastoma that may benefit the clinical management of patients.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30523111 DOI: 10.1126/science.aat6768
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728